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Once upon a time, free radical biology was studied primarily
by physical chemists who minded their electrons in relative
obscurity. That their interests might one day be shared by
clinical cardiologists would have seemed most unlikely. Yet
today, many cardiologists—confused by seemingly contra-
dictory clinical reports, egged on by curious patients and
aggravated by overstated media reports and the billion-
dollar over-the-counter vitamin industry—may wish they
had paid more attention to oxygen metabolism during their
biochemistry lectures. The word on the street, and in the
waiting room, is that antioxidants—in particular, antioxi-
dant vitamins—are sexy, profitable and as wholesome as
mother’s milk. Given this popular impression, why have
careful cardiologists not yet recommended their use on a
broader scale for the treatment or prevention of cardiovas-
cular disease? Simply put, although the scientific rationale,
epidemiologic data and retrospective studies are very con-
vincing, the data from prospective, randomized trials have
failed to show a consistent benefit. To resolve these contra-
dictions, we need a better understanding of the differences
among the various antioxidant vitamins, the means by
which these antioxidants exert their effects and whether all
or some subset of individuals will benefit from the use of
antioxidant vitamins.
Vitamin E: clinical data. Vitamin E has been of particular
interest in recent years, and the mixed data on its use
(reviewed in [1]) are illustrative in considering the potential
influence of the study published in this issue of the Journal
by Saldeen et al. (2). Previously, two prominent, well-
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designed epidemiologic studies linked high vitamin E con-
sumption with a favorable cardiovascular risk profile (3,4),
yet close correlations between serum vitamin E levels and
improved cardiovascular outcomes have not always been
found (5,6). Randomized, prospective clinical trials of vita-
min supplementation have been even more confusing.
Treatment with beta-carotene, a precursor of vitamin A,
was linked to an increased risk of ischemic heart disease in
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
Study (7). For vitamin E, the efficacy demonstrated in
prospective clinical trials has been more promising, but still
inconclusive (Table 1). In the Cambridge Heart Antioxi-
dant Study (CHAOS), patients randomized to vitamin E
supplementation had a significant reduction in the risk of
nonfatal myocardial infarction, but an increase in all-cause
mortality (8). To make matters more confusing, data from
the Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto miocardico (GISSI) prevention study, reported
at the 48th Annual American College of Cardiology Ses-
sions in March 1999 (not yet published), do not demon-
strate a beneficial effect of vitamin E on major cardiovascu-
lar end points. These studies alone are enough to explain the
bewilderment of clinical cardiologists seeking to rationalize
the data regarding antioxidant vitamin prescription.
Sources of oxidative stress. For those attempting to make
sense of the rather ambiguous human studies addressing the
role of antioxidant vitamins in cardiovascular risk reduction,
it may be prudent to consider the sources of the reactive
oxygen species (ROS) that they combat, and the effects
these ROS have on the cardiovascular system. Diet and
environmental factors such as cigarette smoking are impor-
tant direct and indirect sources of oxidative stress (9,10),
which may in part explain their atherogenic effects. How-
ever, endogenous sources of ROS are at least of equal
importance. Cells within blood vessels generate ROS, in-
cluding endothelial and smooth muscle cells (11,12). In-
deed, ROS may directly induce vascular smooth muscle cell
proliferation (13) and are important mediators of the effects
of proatherogenic factors such as platelet-derived growth
factor (14). Our own laboratories have shown that throm-
bin, which has procoagulant, vasoconstricting and prolifer-
ative effects on vascular cells, potently stimulates ROS
through a novel cellular oxidase system (15). Also, as shown
in the study of Saldeen et al. (2), thrombosis itself is likely
a potent initiator of ROS generation in the vasculature.
How do these endogenous ROS, which are predomi-
nantly short-lived species such as hydrogen peroxide and
superoxide anion, result in the long-term changes associated
with atherogenesis? One possibility is that lipids, proteins
and deoxyribonucleic acid (DNA) are oxidatively modified
by ROS, and that these modified proteins have long-lived
and deleterious consequences to the vasculature. The oxi-
dation of low density lipoprotein would be an excellent
example of such a process (16). 4-Hydroxynonenal is an
oxidatively modified fatty acid product with relatively long-
lived effects that may have atherogenic properties (17).
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Oxidative modification of DNA, particularly within the
mitochondrial genome, may also account for some of the
long-term changes in cellular function that result in pro-
gression of atherosclerosis (unpublished data).
Vascular effects of oxidative stress. Increased levels of
ROS, either from endogenous or exogenous sources, have
pleiotropic effects on the vascular system. As mentioned
earlier, they are potent stimuli for smooth muscle cell
proliferation, which is an early event in vascular lesion
formation. Reactive oxygen species such as superoxide anion
also impair endothelium-dependent vasodilation (18), an
effect that may be due at least in part to conversion of nitric
oxide to peroxynitrite. Acting through a similar mechanism,
ROS can promote platelet aggregation (19). Reactive oxy-
gen species may affect the stability of atherosclerotic plaques
through direct toxic effects on the vascular endothelium (20)
by increasing the expression of macrophage-homing pro-
teins such as vascular cell adhesion molecule-1 (21) and by
activating macrophage-derived matrix metalloproteinases
(22). Thus, ROS have the capability to affect virtually every
step of the atherogenic injury process (23).
Effects of alpha- and gamma-tocopherol on variables of
thrombosis and oxidative stress. If ROS influence so
many proatherogenic pathways, how is it possible that
clinical studies testing antioxidant vitamins have yielded no
consistent answers for the physician? The present study by
Saldeen et al. (2) demonstrates that orally administered
vitamin E does indeed have considerable effects on endog-
enous variables of ROS metabolism, and it also has the
ability to block platelet aggregation and thrombus formation
in a rat FeCl3-induced abdominal aorta thrombosis model.
This study is remarkable not only for the close correlation
made between clinically relevant end points (platelet aggre-
gation and thrombosis) and multiple variables of endoge-
nous ROS activity, but also for the differences noted when
rats were fed equal amounts of the two bioavailable forms of
vitamin E—alpha- and gamma-tocopherol. The investiga-
tors found that gamma-tocopherol was significantly more
potent than alpha-tocopherol in inhibiting thrombosis and
in eliciting a favorable profile of oxidative variables. These
results are somewhat surprising and provide a lens through
which the results of clinical trials described earlier might be
viewed a bit more clearly.
To understand the study of Saldeen et al. (2), the biologic
differences between alpha- and gamma-tocopherol should
be considered. The two isoforms differ structurally by a
single methyl group substitution. Alpha-tocopherol has
more potent vitamin E activity than does gamma-
tocopherol (24), is found in higher plasma concentrations
(25) and may itself suppress gamma-tocopherol levels (26).
Alpha-tocopherol is a more potent antioxidant in vitro than
is gamma-tocopherol (27), yet gamma-tocopherol has a
greater capacity to remove potent peroxynitrite-derived
species such as nitric oxide (28). These differences are
particularly relevant because although gamma-tocopherol is
the most abundant form of vitamin E in the diet, oral
vitamin E supplements are exclusively preparations of
alpha-tocopherol (29). Although the nuances of these vita-
min E isoforms are relatively underappreciated, they provide
a potential explanation for why vitamin E supplementation
does not confer the same benefit as high dietary intake of
vitamin E.
If these experiments can be replicated in other models
and with other experimental end points, we will be forced to
ask whether the clinical studies of vitamin E supplementa-
tion using alpha-tocopherol have been misguided. There are
few clinical data to bear on this question; however, it is
interesting to note that only serum levels of gamma-
tocopherol, and not alpha-tocopherol, are reduced in pa-
tients with coronary artery disease (30). It is quite conceiv-
able that vitamin E supplementation for the prevention of
cardiovascular disease might involve a careful prescription
not only of particular isoforms of the vitamin, but also of
precise dosages. This is in contrast to the “megadose”
mentality often displayed by vitamin-gobblers, and would
take considerable education of physicians and their patients
to implement. The experiments of Saldeen et al. (2) also
indicate that a much better fundamental understanding of
the cellular and physiologic effects of antioxidant vitamins is
needed to guide the clinical trials that will help us to decide
which dietary supplements are good and which are not so
good, from a cardiovascular perspective.
Measures of oxidative stress. To compound these difficul-
ties, there remains no good method to determine which
individuals are most likely to benefit from antioxidant
therapies. Imagine the likelihood of determining the efficacy
Table 1. Large, Randomized Trials of Vitamin E Supplementation (i.e., Alpha-Tocopherol) in Patients With Coronary
Artery Disease
Study
(reference) Criteria for Enrollment n
Length of
Follow-Up Dose Effect of Alpha-Tocopherol
Rapola et al. (7) Male smokers with previous MI 1,862 5.3 years 50 mg/day No difference in MI or mortality
CHAOS (8) Angiographically proved CAD 2,002 510 days 800 IU/day for first
546 patients then
400 IU/day
Significant reduction in nonfatal
MI; nonsignificant increase in
CV mortality and all-cause
mortality
CAD 5 coronary artery disease; CHAOS 5 Cambridge Heart Antioxidant Study; CV 5 cardiovascular; MI 5 myocardial infarction.
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of an antihypertensive medication if it was applied to the
population in general, or of using cholesterol-lowering
medications indiscriminately without knowledge of serum
cholesterol values. There are hints that it may be possible to
develop such a marker (or group of markers); the measure-
ment of F2-isoprostanes (31) and a newly reported method
for measuring mitochondrial DNA damage (32) appear
promising but preliminary.
Conclusions. The usefulness of antioxidants for the pre-
vention of cardiovascular diseases has yet to be definitively
proven. However, studies such as those of Saldeen et al. (2)
offer important potential insights that, together with the
development of methods to identify individuals most likely
to benefit, provide hope to clinicians seeking to use antiox-
idant vitamins with safety and efficacy for the treatment and
prevention of cardiovascular disease.
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